Cargando…
FRI431 Erythrocytosis Associated With Oral Testosterone Replacement
Disclosure: A.A. Engel: None. J.L. Sarvaideo: None. Background: A growing prevalence in male hypogonadism has led to increased interest in the most common adverse event, erythrocytosis. Defined by hematocrit (HCT) > 49-51%, the incidence varies depending on the testosterone formulation.(3) The fo...
Autores principales: | Engel, Ashley A, Sarvaideo, Jenna Lynne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554327/ http://dx.doi.org/10.1210/jendso/bvad114.1622 |
Ejemplares similares
-
SUN-210 Testosterone Replacement Therapy Implicated in Osteonecrosis
por: Yang, Almira, et al.
Publicado: (2019) -
ODP412 High Frequency of Erythrocytosis in Hypogonadal Men on Testosterone Replacement Therapy
por: Pérez-Luis, Jesús, et al.
Publicado: (2022) -
Stability of Weekly Intramuscular Estradiol Cypionate in a Transgender Woman
por: Calzada, Stephanie, et al.
Publicado: (2021) -
SUN-LB9 Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women
por: Doll, Elizabeth E, et al.
Publicado: (2020) -
FRI428 VTE And Testosterone Therapy: What Is The Risk?
por: Cheatham, Callie, et al.
Publicado: (2023)